HOW IT WORKS
Bringing the future to you now
Addressing the issue at its Core
A Global Health Crisis
Obesity and diabetes fuel each other through insulin resistance and inflammation, creating a cycle that worsens health, shortens life, and burdens healthcare.
Breaking the Cycle
At Hummsa, we target the root causes of this vicious loop. By addressing the mechanisms that link obesity and diabetes, we aim to restore metabolic balance and slow the cascade of related chronic diseases.
Healthier Aging for All
Our next-generation oral GLP-1 therapies go beyond treatment. By restoring function early, they make prevention possible—bringing healthier, longer lives within reach.
Global Disease Burden
The International Diabetes Federation estimates that
8,400,000
adults worldwide live with diabetes.
Economic burden in 2024
$100B
Economic burden in 2030
$110B
*DALYs : ~1.7 million
*DALYs : Disability-Adjusted Life Years
The International Diabetes Federation estimates that
550,000,000
adults worldwide live with diabetes.
Economic burden in 2024
$880B
Economic burden in 2030
$980B
*DALYs: ~60 million
*DALYs : Disability-Adjusted Life Years
The World Health Organization estimates that
1.23 Billion
worldwide live with obesity
Economic Burden in 2024
$2.5 Tr
Economic burden in 2030
$4 Tr
*DALYs: ~250 million
*DALYs : Disability-Adjusted Life Years
The Journal of Hepatology estimates that
1.4 Billion
worldwide live with MASLD
Economic burden in 2024
$300B
Economic burden in 2030
$400B
*DALYs : ~50 million
*DALYs : Disability-Adjusted Life Years
The International Osteoporosis Foundation estimates that
500 Million
worldwide live with osteoporosis
Economic burden in 2024
$120B
Economic burden in 2030
$160B
*DALYs : ~20 million
*DALYs : Disability-Adjusted Life Years
The Alzheimer’s Disease International estimates that
55,000,000
people worldwide live with Alzheimer's
Economic burden in 2024
$1.2 tr
Economic burden in 2030
$2 tr
& more than 1 in 4 patients experience A 26% reduction in major cardiovascular events.
For the above diseases, today’s treatments fail patients
They arrive too late—after damage is done.
They manage symptoms, not root causes.
They demand costly drugs injections, and complex storage.
They keep patients in maintenance, not recovery.
this is where
comes in
We’re building a new kind of therapy. One that doesn’t just manage disease, but helps the body repair itself.
Our lead candidate, HB PKO02, an oral small molecule GLP-1 Receptor Agonist is designed to regenerate insulin-producing beta cells. By restoring lost function, it reduces or even eliminates the need for insulin.
Because it targets damage early, it can be used to prevent, not just treat disease.
